Kerry Segal Appointed Vice President, Business Development, at IDM
[Going from Cephalon to IDM. On the day when the CIMA acquisition was announced. What gives? Either he fell out completely with Baldino or IDM has some very interesting prospects. But in that case - where?]
PARIS--(BUSINESS WIRE)--Nov. 4, 2003--IDM (Immuno-Designed Molecules), a biopharmaceutical company specialized in the field of cellular immunotherapy, announces that Kerry N. Segal has joined the company as Vice President, Business Development. Mr. Segal will be based in Irvine, Calif., where IDM U.S. operations are located. Mr. Segal is a senior professional in business development, licensing and acquisitions, and brings to IDM approximately 20 years of diverse industry experience in pharmaceutical and biotechnology companies.
Prior to joining IDM, Mr. Segal held the position of Director, Licensing and Acquisitions, at Cephalon, Inc. since 1998. In this position, he was responsible for global licensing, negotiation of agreements and corporate merger/acquisition strategy.
Previously, Mr. Segal worked at several companies in the U.S., including Novartis, Johnson & Johnson, Sandoz Pharmaceuticals, Elkins-Sinn Pharmaceuticals and Bristol Labs Pharmaceutical in various positions in business development, sales and marketing.
Mr. Segal holds an MBA from Temple University.
"We are delighted to welcome Kerry Segal. His expertise in large biotech and pharmaceutical companies will be a critical asset for IDM's development while we continue to search for new international partnerships," said Jean-Loup Romet-Lemonne, President and CEO. |
